Original research article
Porto Biomed. J. 2017; 2(4): 111-114 doi: http://dx.doi.org/doi:10.1016/j.pbj.2017.02.001 (Published 9 March 2017)

Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction

José Pedro L. Nunesa,b,*, Filipa Melãob, Ana Rita Godinhob, Joana D. Rodriguesb, Maria Júlia Maciela,b

Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Department of Cardiology, Hospital São João, Porto, Portugal
*Corresponding author:
Accepted 4 February 2017
abstract
Introduction: Diabetes mellitus is frequently associated to cardiovascular disease. We aimed at studying the relations between anti-diabetic drugs in use at admission by diabetic patients with acute myocardial infarction and survival after a period of at least 36 and up to 52 months after admission. Methods: Retrospective study based on electronic records. Data from a total number of 195 admissions corresponding to different patients were under analysis. Results: Kaplan–Meier analysis, as well as Cox analysis, failed to show a difference in survival associated to the use of DPP-4 inhibitors (n = 35 patients). A non-significant trend toward increased survival was seen with metformin (n = 92 patients), and in the opposite direction with both insulin (n = 51 patients) and sulfonylureas (n = 51 patients). Conclusions: The use of DPP-4 inhibitors at admission, in patients with Diabetes mellitus admitted for acute myocardial infarction, was not associated to a different survival after no less than 36 months and up to 52 months after admission.
keywords
Acute myocardial infarction; Diabetes mellitus; DPP-4 inhibitors; Sulfonylureas
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.